Perspective on measurable residual disease testing in acute myeloid leukemia von Walter, Roland B.

Volltext

Measurable residual disease in haematological and solid cancers von Walter, Roland B., Gale, Robert Peter

Volltext

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party von Schuurhuis, Gerrit J., Heuser, Michael, Freeman, Sylvie, Béné, Marie-Christine, Buccisano, Francesco, Cloos, Jacqueline, Grimwade, David, Haferlach, Torsten, Hills, Robert K., Hourigan, Christopher S., Jorgensen, Jeffrey L., Kern, Wolfgang, Lacombe, Francis, Maurillo, Luca, Preudhomme, Claude, van der Reijden, Bert A., Thiede, Christian, Venditti, Adriano, Vyas, Paresh, Wood, Brent L., Walter, Roland B., Döhner, Konstanze, Roboz, Gail J., Ossenkoppele, Gert J.

Volltext

The present and future of measurable residual disease testing in acute myeloid leukemia von Blachly, James S, Walter, Roland B, Hourigan, Christopher S

Volltext

Targeting MCL-1 in hematologic malignancies: Rationale and progress von Wei, Andrew H., Roberts, Andrew W., Spencer, Andrew, Rosenberg, Aaron Seth, Siegel, David, Walter, Roland B., Caenepeel, Sean, Hughes, Paul, McIver, Zach, Mezzi, Khalid, Morrow, Phuong Khanh, Stein, Anthony

Volltext

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? von Araki, Daisuke, Wood, Brent L, Othus, Megan, Radich, Jerald P, Halpern, Anna B, Zhou, Yi, Mielcarek, Marco, Estey, Elihu H, Appelbaum, Frederick R, Walter, Roland B

Volltext

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study von Wei, Andrew H, Strickland, Jr, Stephen A, Hou, Jing-Zhou, Fiedler, Walter, Lin, Tara L, Walter, Roland B, Enjeti, Anoop, Tiong, Ing Soo, Savona, Michael, Lee, Sangmin, Chyla, Brenda, Popovic, Relja, Salem, Ahmed Hamed, Agarwal, Suresh, Xu, Tu, Fakouhi, Kaffa M, Humerickhouse, Rod, Hong, Wan-Jen, Hayslip, John, Roboz, Gail J

Volltext

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy von Walter, Roland B., Appelbaum, Frederick R., Estey, Elihu H., Bernstein, Irwin D.

Volltext

The past and future of CD33 as therapeutic target in acute myeloid leukemia von Laszlo, George S, Estey, Elihu H, Walter, Roland B

Volltext

Minimal Residual Disease Testing After Induction Chemotherapy for Acute Myeloid Leukemia: Moving Beyond Prognostication? von Walter, Roland B

Volltext

CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia von Green, Margaret L., Leisenring, Wendy M., Xie, Hu, Walter, Roland B., Mielcarek, Marco, Sandmaier, Brenda M., Riddell, Stanley R., Boeckh, Michael

Volltext

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis von Buckley, Sarah A, Wood, Brent L, Othus, Megan, Hourigan, Christopher S, Ustun, Celalettin, Linden, Michael A, DeFor, Todd E, Malagola, Michele, Anthias, Chloe, Valkova, Veronika, Kanakry, Christopher G, Gruhn, Bernd, Buccisano, Francesco, Devine, Beth, Walter, Roland B

Volltext

Evaluating measurable residual disease in acute myeloid leukemia von Ravandi, Farhad, Walter, Roland B., Freeman, Sylvie D.

Volltext

Elihu H. Estey, MD: Leukaemia expert, statistician, and gentle soul (July 15, 1946–October 8, 2021) von Walter, Roland B., Gale, Robert Peter

Volltext

Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models von Walter, Roland B., Estey, Elihu H.

Volltext

Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment von WALTER, Roland B, OTHUS, Megan, BORTHAKUR, Gautam, RAVANDI, Farhad, CORTES, Jorge E, PIERCE, Sherry A, APPELBAUM, Frederick R, KANTARJIAN, Hagop A, ESTEY, Elihu H

Volltext

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531 von Lamba, Jatinder K, Chauhan, Lata, Shin, Miyoung, Loken, Michael R, Pollard, Jessica A, Wang, Yi-Cheng, Ries, Rhonda E, Aplenc, Richard, Hirsch, Betsy A, Raimondi, Susana C, Walter, Roland B, Bernstein, Irwin D, Gamis, Alan S, Alonzo, Todd A, Meshinchi, Soheil

Volltext

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission von Walter, Roland B., Buckley, Sarah A., Pagel, John M., Wood, Brent L., Storer, Barry E., Sandmaier, Brenda M., Fang, Min, Gyurkocza, Boglarka, Delaney, Colleen, Radich, Jerald P., Estey, Elihu H., Appelbaum, Frederick R.

Volltext

Significance of measurable residual disease in adults with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation von Rodríguez-Arbolí, Eduardo, Orvain, Corentin, Othus, Megan, Walter, Roland B.

Volltext

Comparing Object Recognition in Humans and Deep Convolutional Neural Networks—An Eye Tracking Study von van Dyck, Leonard Elia, Kwitt, Roland, Denzler, Sebastian Jochen, Gruber, Walter Roland

Volltext